Study explorer (study characteristics and results) method abbreviations pdf   xlsx

display ongoing studies
Study Ref. Design studied treatmentcontrol treatmentpatientsstudy risk of biassample sizes Results

COVID 19 hospitalized meta-analysis

Nouri-Vaskeh
  IRCT20180802040678N4		 RCTangiotensin receptor blockers (ARBs)calcium channel blockerCOVID 19 hospitalizedsome concern
41/41 inconclusive
  • inconclusive 65 % decrease in deaths (PE) with a moderate degree of certainty due to some concern in risk of bias
Duarte
  NCT04355936		 RCTangiotensin receptor blockers (ARBs)standard of careCOVID 19 hospitalizedhigh
41/41 suggested
  • suggested 1.2-fold increase in hospital discharge but with a low degree of certainty due to high risk of bias
REPLACE
  NCT04338009		 RCTdiscontinuation of ACEI/ARBcontinuation of ACEI/ARBCOVID 19 hospitalizedNA
77/75 inconclusive

    COVID 19 all comers meta-analysis

    Li OBSRenin-angiotensin-system-acting agentscontrolCOVID 19 all comerscritical
    		-/- inconclusive
      Meng OBSRenin-angiotensin-system-acting agentscontrolCOVID 19 all comerscritical
      		17/25 inconclusive
        Yang OBSRenin-angiotensin-system-acting agentscontrolCOVID 19 all comersserious
        		43/83 inconclusive
          Zhang OBSRenin-angiotensin-system-acting agentscontrolCOVID 19 all comersserious
          		188/940 suggested
          • suggested 63 % decrease in deaths but with a low degree of certainty due to high risk of bias
          Bean OBSRenin-angiotensin-system-acting agentscontrolCOVID 19 all comersserious
          		37/168 suggested
          • suggested 71 % decrease in death or transfer to ICU but with a low degree of certainty due to high risk of bias
          Yan et al. OBSangiotensin converting enzyme inhibitors (ACEIs)controlCOVID 19 all comerscritical
          		-/- inconclusive
            Yan et al. OBSangiotensin receptor blockers (ARBs)controlCOVID 19 all comerscritical
            		-/- inconclusive

              COVID-19 mild to moderate meta-analysis

              Lopes (BRACE CORONA)
                              NCT04364893              		 RCTdiscontinuation of ACEI/ARBcontinuation of ACEI/ARBCOVID-19 mild to moderatesome concern
              		371/369 inconclusive

                PE: primary endpoint; (a): to be demonstrated a result must be statistically significant on a primary endpoint (with multiplicity adjustment if necessary);
                Study risk of bias assessed for the study primary endpoint(s) or the main endpoints in case of no formally defined primary endpoint(s).

                 

                - About us - Contact us - Method - RSS Made with in Lyon - Credits - Privacy policy - Licence Creative Commons